Di Cesare A, Rosi E, Trovato E, Pescitelli L, Panduri S, Manzo Margiotta F, et al. Therapeutic Modulation Of Peripheral Blood Cells And Inflammatory Indices During 52 Weeks Of Risankizumab In Responder Patients With Moderate-to-Severe Psoriasis: Results From A Multicenter Prospective Study. Dermatol Pract Concept [Internet]. 2025 Oct. 31 [cited 2026 Apr. 25];15(4):5733. Available from: https://www.dpcj.org/index.php/dpc/article/view/5733